196 related articles for article (PubMed ID: 26526739)
1. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
2. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
Zhou ZZ; Ge BC; Zhong QP; Huang C; Cheng YF; Yang XM; Wang HT; Xu JP
Eur J Med Chem; 2016 Nov; 124():372-379. PubMed ID: 27597413
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
Brullo C; Massa M; Rocca M; Rotolo C; Guariento S; Rivera D; Ricciarelli R; Fedele E; Fossa P; Bruno O
J Med Chem; 2014 Aug; 57(16):7061-72. PubMed ID: 25126889
[TBL] [Abstract][Full Text] [Related]
4. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
Brullo C; Massa M; Villa C; Ricciarelli R; Rivera D; Pronzato MA; Fedele E; Barocelli E; Bertoni S; Flammini L; Bruno O
Bioorg Med Chem; 2015 Jul; 23(13):3426-35. PubMed ID: 25936260
[TBL] [Abstract][Full Text] [Related]
6. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Gangwal RP; Damre MV; Das NR; Dhoke GV; Bhadauriya A; Varikoti RA; Sharma SS; Sangamwar AT
J Mol Graph Model; 2015 Apr; 57():89-98. PubMed ID: 25687765
[TBL] [Abstract][Full Text] [Related]
7. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Purushothaman B; Arumugam P; Kulsi G; Song JM
Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
[TBL] [Abstract][Full Text] [Related]
11. Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
Chłoń-Rzepa G; Ślusarczyk M; Jankowska A; Gawalska A; Bucki A; Kołaczkowski M; Świerczek A; Pociecha K; Wyska E; Zygmunt M; Kazek G; Sałat K; Pawłowski M
Eur J Med Chem; 2018 Oct; 158():517-533. PubMed ID: 30245393
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK
Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213
[TBL] [Abstract][Full Text] [Related]
13. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ
Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds.
Xing M; Akowuah GA; Gautam V; Gaurav A
J Biomol Struct Dyn; 2017 Oct; 35(13):2910-2924. PubMed ID: 27608741
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.
Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB
J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Liao Y; Guo Y; Li S; Wang L; Tang Y; Li T; Chen W; Zhong G; Song G
Bioorg Med Chem Lett; 2018 Apr; 28(7):1188-1193. PubMed ID: 29545101
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
